EP3305779A1 — Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Assigned to Taiho Pharmaceutical Co Ltd · Expires 2018-04-11 · 8y expired
What this patent protects
An objective of the present invention is to obtain a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrim idinedione hydrochloride. The present invention provides a crystal of 5-chloro-6-(2-iminopyrrolidin-l-yl)methyl-2,4(1H,3H)-pyrim idinedione hydro…
USPTO Abstract
An objective of the present invention is to obtain a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrim idinedione hydrochloride. The present invention provides a crystal of 5-chloro-6-(2-iminopyrrolidin-l-yl)methyl-2,4(1H,3H)-pyrim idinedione hydrochloride exhibiting characteristic peaks at angles of 11.6°, 17.2°, 17.8°, 23.3°, 27.1°, and 29.3° as a diffraction angle (2θ ± 0.1°) in powder X-ray diffraction.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.